Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset
Josée Perreault, Tony Tremblay, Marie-Josée Fournier, Mathieu Drouin, Guillaume Beaudoin-Bussières, Jérémie Prévost, Antoine Lewin, Philippe Bégin, Andrés Finzi, Renée Bazin, Josée Perreault, Tony Tremblay, Marie-Josée Fournier, Mathieu Drouin, Guillaume Beaudoin-Bussières, Jérémie Prévost, Antoine Lewin, Philippe Bégin, Andrés Finzi, Renée Bazin
Abstract
Perreault and colleagues examined antibody titers in sequential samples from serum donors recovering from COVID-19 and demonstrated that antibody titers fall over 3-4 months. These results have important implications for convalescent serum collection and seroprevalence studies.
Figures
References
- Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA. 2020;117(17):9490–9496.
- Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582–1589.
- Zhang B, Liu S, Tan T, et al. Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection. Chest. 2020;158(1):e9–e13.
- Dzik S. COVID-19 convalescent plasma: now is the time for better science. Transfus Med Rev. 2020;34(3):141–144.
- Ye M, Fu D, Ren Y, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol. 2020;92(10):1890–1901.
- Zeng Q-L, Yu Z-J, Gou J-J, et al. Effect of convalescent plasma therapy on viral shedding and survival in COVID-19 patients. J Infect Dis. 2020;222(1):38–43.
- Hegerova L, Gooley TA, Sweerus KA, et al. Use of convalescent plasma in hospitalized patients with COVID-19: case series. Blood. 2020;136(6):759–762.
- Rojas M, Rodríguez Y, Monsalve DM, et al. Convalescent plasma in COVID-19: possible mechanisms of action. Autoimmun Rev. 2020;19(7):102554.
- Rajendran K, Krishnasamy N, Rangarajan J, et al. Convalescent plasma transfusion for the treatment of COVID‐19: systematic review. J Med Virol. 2020;92:1475–1483.
- Gharbharan A, Jordans CCE, Geurtsvankessel C. Convalescent plasma for COVID-19. A randomized clinical trial [published online ahead of print 3 July 2020]. medRxiv. 3 July 2020 10.1101/2020.07.01.20139857.
- Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020;324(5):460–470.
- Ni L, Ye F, Cheng M-L, et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity. 2020;52(6):971–977.e3.
- Wu F, Wang A, Liu M, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications [published online ahead of print 20 April 2020] medRxiv. 20 April 2020 10.1101/2020.03.30.20047365.
- Jackson LA, Anderson EJ, Rouphael NG, et al. mRNA-1273 Study Group An mRNA vaccine against SARS-CoV-2: preliminary report [published online ahead of print 14 July 2020] N Engl J Med. 14 July 2020 doi: 10.1056/NEJMoa2022483.
- Beaudoin-Bussières G, Laumaea A, Anand SP, et al. Decline of humoral responses against SARS-CoV-2 spike in convalescent Individuals. mBio. 2020;11(5):e02520–e02590.
- Prévost J, Gasser R, Beaudoin-Bussières G, et al. Cross-sectional evaluation of humoral responses against SARS-CoV-2 spike. Cell Rep Med. 2020;1(7):100126.
- Zhang G, Nie S, Zhang Z, Zhang Z. longitudinal change of severe acute respiratory syndrome coronavirus 2 antibodies in patients with coronavirus disease 2019. J Infect Dis. 2020;222(2):183–188.
- Long Q-X, Liu B-Z, Deng H-J, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26(6):845–848.
- Lynch KL, Whitman JD, Lacanienta NP, et al. Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity. Clinical Infectious Diseases. 2020:ciaa979.
- Long Q-X, Tang X-J, Shi Q-L, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26(8):1200–1204.
- Seow J, Graham C, Merrick B, et al. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection [published online ahead of print 11 July 2020] medRxiv. 11 July 2020 doi: 10.1101/2020.07.09.20148429.
- Wang K, Long Q-X, Deng H-J, et al. Longitudinal dynamics of the neutralizing antibody response to SARS-CoV-2 infection. Clin Infect Dis. 2020:ciaa1143.
- Morell A, Terry WD, Waldmann TA. Metabolic properties of IgG subclasses in man. J Clin Invest. 1970;49(4):673–680.
- Amanna IJ, Slifka MK. Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol Rev. 2010;236(1):125–138.
- Sekine T, Perez-Potti A, Rivera-Ballesteros O, et al. Karolinska COVID-19 Study Group Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell. 2020;183(1):158–168.
- Woloshin S, Patel N, Kesselheim AS. False negative tests for SARS-CoV-2 infection—challenges and implications. N Engl J Med. 2020;383:e38.
- Mallapaty S. Will coronavirus antibody tests really change everything? Nature. 2020;580:571–572.
- Xia X, Li K, Wu L, et al. Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion. Blood. 2020;136(6):755–759.
Source: PubMed